Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects With Recurrent or Progressive Grade 4 Glioma

NCT07384390 is registered in ClinicalTrials.gov with Shanghai Tongji Hospital, Tongji University School of Medicine as lead sponsor.

NCT NCT07384390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07384390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Escalation, Multiple Administration, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Anti-tumor Activity of TH-CART-027 Cell Injection in Subjects With Recurrent or Progressive Grade 4 Glioma
Lead sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 30, 2026
Completion date
August 31, 2029
Enrollment
21 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

r/r grade 4 glioma